Two clinical pilot studies investigating whether T cells genetically engineered to express NGFR/CD271 improve the recognition and eradication of melanoma cells in patients with stage III–IV melanoma, started in 2012 and 2013 (NCT01955460, NCT01740557). Here, NGFR is linked to melanoma.